Jump to content


Recommended Posts

  • Root Admin


Epsolay, aka, VERED, S5G4T-1 and DER 45 EV, has reached Phase III clinical trial status according to Drug Development Technology. Epsolay is developed and promoted by Sol-Gel Technologies as "an innovative topical encapsulated benzoyl peroxide cream with a 5% concentration for the treatment of papulopustular rosacea."  Epsolay is designed for those who suffer from Phenotype 4

Usually benzoyl peroxide exacerbates rosacea, but Epsolay is a "silica-based microencapsulation delivery system creates a silica barrier between benzoyl peroxide crystals and the skin, and as a result is expected to reduce irritation typically associated with topical application of benzoyl peroxide, thereby making the drug tolerable to rosacea-affected skin." [1]

In a press release, June 18, 2018, Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel, states, “Epsolay is aimed to address the need for more effective treatments for inflammatory papules and pustules of rosacea, a chronic condition for which patients often have low adherence to current drugs.”

Sol-Gel Technologies Ltd., Israel 

As more information is released it will be posted in this thread. If you are a member you can use the 'Notify me of replies' button near the bottom of this post and turn it on for any updates. 

End Notes

[1] Sol-Gel > Pipeline > VERED 

Link to comment
Share on other sites

  • 9 months later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...

Important Information

Terms of Use